UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 518

Sortiert nach

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

British journal of cancer, 2013-04, Vol.108 (8), p.1571-1578

2013

Volltextzugriff (PDF)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

British journal of cancer, 2014-06, Vol.110 (12), p.2821-2828

2014

Volltextzugriff (PDF)

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial

Japanese journal of clinical oncology, 2013-06, Vol.43 (6), p.616-628

2013

Volltextzugriff (PDF)

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Annals of oncology, 2010-02, Vol.21 (2), p.297-304

2010

Volltextzugriff (PDF)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

British journal of cancer, 2012-10, Vol.107 (8), p.1277-1285

2012

Volltextzugriff (PDF)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

British journal of cancer, 2012-10, Vol.107 (8), p.1268-1276

2012

Volltextzugriff (PDF)

359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib

European journal of cancer (1990), 2014-11, Vol.50, p.116-116

2014

Volltextzugriff (PDF)

Does acid etching enhance remineralisation of arrested white spot lesions?

European archives of paediatric dentistry, 2014-12, Vol.15 (6), p.413-419

2014

Volltextzugriff (PDF)

3006 POSTER DISCUSSION Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC)

European journal of cancer (1990), 2011, Vol.47, p.S224-S224

2011

Volltextzugriff (PDF)

7103 ORAL Association of Single Nucleotide Polymorphisms (SNPs) in VEGF Pathway Genes With Progression-free Survival (PFS) and Blood Pressure (BP) in Metastatic Renal Cell Carcinoma (mRCC) in the Phase 3 Trial of Axitinib Versus Sorafenib (AXIS Trial)

European journal of cancer (1990), 2011, Vol.47, p.S505-S505

2011

Volltextzugriff (PDF)

P151 - Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

European urology, 2024-03, Vol.85, p.S213-S214

2024

Volltextzugriff (PDF)

Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

European urology, 2024-03, Vol.85, p.S213-S214

2024

Volltextzugriff (PDF)

Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results

Annals of oncology, 2016-10, Vol.27, p.vi266-vi266

2016

Volltextzugriff (PDF)

Long-Term Safety with Axitinib in Advanced Renal Cell Carcinoma

Annals of oncology, 2014-09, Vol.25, p.iv293

2014

Volltextzugriff (PDF)

843PLONG-TERM SAFETY WITH AXITINIB IN ADVANCED RENAL CELL CARCINOMA

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv293-iv294

2014

Volltextzugriff (PDF)

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS4-07-GS4-07

2018

Volltextzugriff (PDF)

Long-term duration of axitinib treatment in advanced renal cell carcinoma

Annals of oncology, 2016-10, Vol.27, p.vi287-vi287

2016

Volltextzugriff (PDF)

Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27, p.vi449-vi449

2016

Volltextzugriff (PDF)

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

OncoTargets and therapy, 2015-01, Vol.8 (default), p.1363-1373

2015

Volltextzugriff (PDF)

1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC)

European journal of cancer supplements, 2009, Vol.7 (2), p.130-130

2009

Volltextzugriff (PDF)

Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors

Annals of oncology, 2012-09, Vol.23, p.ix262

2012

Volltextzugriff (PDF)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma

OncoTargets and therapy, 2016-01, Vol.9 (Issue 1), p.2855-2863

2016

Volltextzugriff (PDF)

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

British journal of cancer, 2014-01, Vol.110 (4), p.875-881

2014

Volltextzugriff (PDF)

Design aspects and performance of cost-efficient packaged power amplifiers

2015 IEEE International Conference on Microwaves, Communications, Antennas and Electronic Systems (COMCAS), 2015, p.1-4

2015

Volltextzugriff (PDF)

4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib

European journal of cancer supplements, 2007, Vol.5 (4), p.300-300

2007

Volltextzugriff (PDF)

1 – 25 von 518

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(461)
Mit Volltextzugriff
(469)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib

Does acid etching enhance remineralisation of arrested white spot lesions?

3006 POSTER DISCUSSION Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC)

7103 ORAL Association of Single Nucleotide Polymorphisms (SNPs) in VEGF Pathway Genes With Progression-free Survival (PFS) and Blood Pressure (BP) in Metastatic Renal Cell Carcinoma (mRCC) in the Phase 3 Trial of Axitinib Versus Sorafenib (AXIS Trial)

P151 - Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk BioChemically Recurrent prostate cancer (BCR) following Radical Prostatectomy (RP) or Radiation Therapy (RT): EMBARK post hoc analysis

Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results

Long-Term Safety with Axitinib in Advanced Renal Cell Carcinoma

843PLONG-TERM SAFETY WITH AXITINIB IN ADVANCED RENAL CELL CARCINOMA

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

Long-term duration of axitinib treatment in advanced renal cell carcinoma

Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC)

Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

Design aspects and performance of cost-efficient packaged power amplifiers

4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib

Suchergebnisse filtern